Core Insights - Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) has received Breakthrough Therapy Designation from the U.S. FDA for treating advanced head and neck squamous cell carcinoma in patients who have progressed after platinum-based chemotherapy and PD-1/PD-L1 inhibitors [1][2] Group 1: FDA Designation and Clinical Data - The Breakthrough Therapy Designation is based on clinical data showing rapid and durable responses in heavily pretreated patients, indicating a significant need for new therapies in this area [1][2] - The designation expands the application of RYBREVANT FASPRO™ beyond its current approval for non-small cell lung cancer [1][2] - The clinical activity supporting this designation comes from the Phase 1b/2 OrigAMI-4 study, which demonstrated promising results in a challenging patient population [1][2] Group 2: Treatment Mechanism and Patient Impact - RYBREVANT FASPRO™ targets both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET) pathways, which are overexpressed in HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma [1][2] - The dual targeting approach has shown meaningful clinical benefits in lung cancer, with the aim of improving patient outcomes in head and neck cancer as well [1][2] Group 3: Ongoing Studies and Future Directions - RYBREVANT FASPRO™ is currently being evaluated in the ongoing Phase 3 OrigAMI-5 study, which compares its efficacy in combination with pembrolizumab and carboplatin against standard treatments [1][2] - The FDA's Breakthrough Therapy Designation aims to expedite the development and regulatory review process for therapies that show substantial improvement over existing options [1][2] Group 4: Background on Head and Neck Cancer - Head and neck squamous cell carcinoma accounts for over 90% of head and neck cancer cases and approximately 4.5% of all cancers globally, with a significant portion being HPV-negative, which is associated with poorer prognosis [1][2] - Despite advancements in treatment, many patients progress to advanced, recurrent, or metastatic disease, highlighting the urgent need for new therapeutic options [1][2]

Core Viewpoint - Knight Therapeutics Inc. has submitted a marketing authorization application for NIKTIMVO (axatilimab) in Brazil for treating chronic graft-versus-host disease (GVHD) after failure of at least two prior systemic therapies in patients aged 6 years and older [1] Company Developments - Knight Therapeutics expanded its agreement with Incyte for exclusive distribution rights of retifanlimab and axatilimab in Latin America, with Incyte responsible for development and supply, while Knight handles regulatory approvals and distribution [2] - NIKTIMVO received FDA approval in August 2024 for chronic GVHD treatment in patients weighing at least 40 kg after failure of two prior systemic therapies [3] - The CEO of Knight emphasized the importance of new treatment options for chronic GVHD patients, highlighting the company's commitment to improving patient access to effective therapies [4] Industry Context - Chronic GVHD is a significant complication following allogeneic stem cell transplantation, affecting 30%-70% of recipients globally, with approximately 1,400 to 1,800 allogeneic transplants reported annually in Brazil [5] - The cumulative incidence of chronic GVHD after two years is reported to be 29.5% based on recent analyses [5] - NIKTIMVO is a first-in-class CSF-1R-blocking antibody, with ongoing studies for its efficacy in combination therapies for chronic GVHD and other conditions [6][8]

February 2026 Investor Presentation We're in. For patients. 1 Forward Looking Statements The forward-looking statements in this presentation are based upon the Company's current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed, projected, anticipated or indicated in any ...

Core Viewpoint - Aquestive Therapeutics has appointed Dr. Matthew Greenhawt as Chief Medical Officer to support the resubmission of the Anaphylm™ New Drug Application (NDA) and advance its clinical pipeline [1][2][3] Company Leadership and Expertise - Dr. Greenhawt is an internationally recognized expert in allergy and immunology, bringing extensive clinical, research, and advocacy experience to the company at a critical time [2][4] - The appointment is seen as a strong addition to the leadership team, with Dr. Greenhawt's expertise expected to be invaluable for FDA approval efforts [3] Product Development - Anaphylm™ (dibutepinephrine) is a sublingual film designed for the emergency treatment of anaphylaxis, which is expected to be the first oral medication for severe allergic reactions if approved by the FDA [7] - The product is designed to be user-friendly, dissolving on contact without the need for water or swallowing, and is compact enough to be carried easily [7] Company Background - Aquestive Therapeutics focuses on advancing medicines through innovative science and delivery technologies, operating as both a product developer and a Contract Development and Manufacturing Organization (CDMO) [8] - The company has a portfolio that includes four commercialized products and is advancing multiple product candidates, including Anaphylm and AQST-108 for various indications [8]

AC Immune (ACIU) has disclosed that its partner Janssen Pharmaceuticals of Johnson & Johnson (JNJ) has temporarily paused enrollments in a mid-stage trial for their jointly developed Alzheimer’s candidate ACI-35.030/JNJ-2056. The companies are advancing ACI-35.030/JNJ-2056 as part of a licensing ...

Economic Indicators - U.S. February Empire State manufacturing index fell to 7.1, a smaller decline than expectations of 6.4 [3] - Economists expect December Durable Goods Orders to drop -1.8% month-over-month, while Core Durable Goods Orders are expected to rise +0.3% month-over-month [8] - U.S. Building Permits for December are expected to be 1.400 million and Housing Starts to be 1.310 million [9] - Industrial Production and Manufacturing Production are expected to rise +0.4% month-over-month in January [10] Federal Reserve Insights - U.S. rate futures indicate a 92.1% probability of no rate change and a 7.9% chance of a 25 basis point rate cut at the next FOMC meeting in March [1] - Fed Governor Michael Barr stated that interest rates should remain unchanged until clearer evidence of inflation moving toward the 2% target is seen [2] - The minutes from the Fed's January meeting will be closely scrutinized to assess the debate on rate cuts versus keeping rates steady [7] Stock Market Movements - Wall Street's main stock indexes ended positively, with Norwegian Cruise Line Holdings surging over +12% after Elliott Investment Management acquired a more than 10% stake [4] - Southwest Airlines climbed more than +6% after UBS upgraded the stock to Buy with a price target of $73 [4] - ZIM Integrated Shipping Services jumped over +25% following an acquisition agreement with Hapag-Lloyd for $4.2 billion [4] - Genuine Parts tumbled more than -14% after posting downbeat Q4 results and announcing plans to split its auto and industrial parts units [4] Corporate Earnings - Prominent companies such as Analog Devices, Booking Holdings, Carvana, DoorDash, and Occidental Petroleum are set to release quarterly results [11] - Cadence Design Systems climbed more than +7% in pre-market trading after posting upbeat Q4 results and issuing solid FY26 guidance [18] - Palo Alto Networks slumped more than -6% in pre-market trading after cutting its full-year adjusted EPS guidance [18] International Market Developments - The Euro Stoxx 50 Index is up +0.97%, supported by strong gains in defense and bank stocks [13] - U.K. January CPI fell -0.5% month-over-month and rose +3.0% year-over-year, while January Core CPI fell -0.6% month-over-month and rose +3.1% year-over-year [14] - Japan's January Trade Balance stood at -1,152.7 billion yen, with exports rising +16.8% year-over-year [16]

In the race to lead the innovation narrative, the US healthcare industry needs to actively consider systemic changes to contend with the growing competition from China, say industry experts. At the glitzy event organised by the lobbying group PhRMA on 17 February in Washington DC, several administration leaders mingled with leading pharma and biotech executives to discuss the latest trends and challenges in the pharmaceutical sector. The chief topic on the agenda for all was China; with PhRMA and others ...

Economic Outlook - The Bank of England is urged to implement quick interest rate cuts to alleviate the cost-of-living crisis and boost consumer spending and business confidence [1][2] - Trade unions support interest rate cuts, citing easing inflation as beneficial for working families, with expectations of further softening due to government support for energy bills and other costs [2] - Firms are looking for inflation easing to be accompanied by measures to reduce business costs, such as business rates reform, to stimulate economic growth [3] Inflation and Interest Rates - The Consumer Price Index (CPI) has dropped to 3.0%, the lowest level in nearly a year, indicating potential for interest rate cuts by the Bank of England [25][28] - Analysts predict a 25 basis point cut in interest rates at the next Bank of England meeting, with further cuts anticipated if inflation continues to decline [19][21][20] - Despite the drop in headline inflation, services inflation remains sticky, suggesting caution from the Monetary Policy Committee [22] Market Performance - The FTSE 100 index has reached new record highs, driven by gains in sectors such as mining, defense, and banking [6][15][28] - BAE Systems has reported a 10% increase in sales to £30.7 billion and a record order book of £83.6 billion, reflecting strong demand in the defense sector [23][10] - Glencore's revenue for 2025 increased by 7% to $247.54 billion, with adjusted EBIT falling less than expected, indicating resilience in the mining sector [16][17] Company-Specific Developments - BAE Systems has increased its dividend by 10% and expects sales growth of 7-9% for the current year, supported by rising global defense spending [23][13] - Glencore's performance improved significantly in the second half of the year, aided by stronger metals prices and higher copper output [17] - BAE's free cash flow is projected to exceed £1.3 billion, contributing to a reduction in net debt by 22% [13][24]

Core Insights - The Zacks Equity Research team has highlighted several stocks, including AbbVie Inc., RTX Corp., International Business Machines Corp., EVI Industries, Inc., and Rocky Mountain Chocolate Factory, Inc. in their Analyst Blog [1][2] AbbVie Inc. (ABBV) - AbbVie shares have increased by 13.8% over the past six months, while the Zacks Large Cap Pharmaceuticals industry has gained 29.5% [4] - The company exceeded fourth-quarter estimates for both earnings and sales, successfully managing the loss of exclusivity for Humira by launching new immunology drugs, Skyrizi and Rinvoq, which are performing well [4][5] - AbbVie's neuroscience portfolio is also contributing to revenue growth, with robust net sales growth reported in 2025, marking the second full year post-Humira's loss of exclusivity [5] RTX Corp. (RTX) - RTX shares have outperformed the Zacks Aerospace - Defense industry, gaining 29.2% compared to 11.7% over the past six months [6] - The company reported fourth-quarter earnings and revenues that surpassed estimates, benefiting from strong orders for defense products from the Pentagon and foreign allies [6][7] - RTX's backlog reached $268 billion as of December 31, 2025, supported by improving global commercial air traffic [8] International Business Machines Corp. (IBM) - IBM shares have risen by 10.8% over the past six months, while the Zacks Computer - Integrated Systems industry has gained 61.4% [9] - The company reported strong fourth-quarter results, with adjusted earnings and revenues exceeding estimates, driven by growth in hybrid cloud, AI-powered automation, and enterprise consulting [9][10] - IBM is focusing on its Watsonx platform for AI capabilities and quantum technology, although it faces challenges from traditional business weaknesses and high debt levels [11] EVI Industries, Inc. (EVI) - EVI shares have outperformed the Zacks Industrial Services industry, increasing by 24.4% over the past year [12] - The company reported a 24% revenue increase in the December quarter and a 20% rise for the first six months of FY26, with gross margin expanding to approximately 31% [12][13] - Despite solid revenue growth, net income has dipped due to rising SG&A expenses, and the company faces increased working capital demands [14] Rocky Mountain Chocolate Factory, Inc. (RMCF) - Rocky Mountain shares have outperformed the Zacks Retail - Restaurants industry, gaining 51.1% over the past year [15] - The company is focusing on margin improvement, with manufacturing gross margin rising to 21.4% from 10%, and EBITDA turning positive [15][16] - However, Rocky Mountain faces liquidity risks and high-cost debt, which could impact its operational stability [17]

Core Insights - Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is recognized as one of the seven cheap pharmaceutical stocks to consider for investment according to hedge funds [1] - The company has received a price target increase from Truist Securities, reflecting confidence in its pain management portfolio and ongoing product momentum [2] Financial Outlook - Collegium expects net product revenue for the year 2026 to be between $805 million and $825 million, with Jornay PM projected to contribute at least $190 million to $200 million [3] - The adjusted EBITDA is anticipated to range from $455 million to $475 million, indicating strong profitability and effective cost management [3] Business Focus - Collegium is focused on developing and commercializing innovative pain management therapies, including abuse-deterrent opioid formulations, aimed at improving patient safety and treatment outcomes [4]